Last updated: 2026-09-14 11:06:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Fulcrum Therapeutics, Inc. (FULC) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3,79, with a market capitalization of $289,93M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2,83 to $15,74. This page covers its latest market performance, valuation, price trends and company information.
$289,93M | |
$3,81 | |
$33,10 | |
$2,25 | |
$3,80 | |
178,00 | |
2,09M | |
-- | |
$15,74 | |
$2,83 | |
-- | |
-- |
Fulcrum Therapeutics, Inc. (FULC) is trading at $3,79 in pre-market trading as of 2026-09-14 10:55:00, down 0,37% ($0,01) from the previous close of $3,80
Pre-market trading shows how investors are pricing FULC before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Fulcrum Therapeutics, Inc. (FULC) moved from $3,85 to $3,79, representing a decline of 1,66% ($0,06).
The stock traded between $3,78 and $3,91 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 1,24 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 7,4%
FULC is currently trading at $3,79, placing it 7,4% of the way from its 52-week low of $2,83 to its 52-week high of $15,74. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 55 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Fulcrum Therapeutics, Inc. (FULC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.